Taysha Gene Therapies, Inc. [Rocket]

In millions, except per share items	Jun-30-23	Mar-31-23	Sep-30-22	Jun-30-22	Mar-31-22	Dec-31-21	Sep-30-21	Jun-30-21
	10-Q	10-Q	10-Q	10-Q	10-Q	10-K	10-Q	10-Q
Revenues			0.0	0.0	0.0	0.0	0.0	0.0
Cost of goods sold			0.0	0.0	0.0	0.0	0.0	0.0
Gross profit			0.0	0.0	0.0	0.0	0.0	0.0
Selling, general and administrative [+]			103.5	106.0	82.7	41.3	35.6	28.5
Sales and marketing				83.0	49.7
General and administrative			20.5			41.3	35.6	28.5
Research and development			54.3			131.9	106.3	77.8
Other operating expenses				0.7	-0.8
EBITDA [+]			-158.0			-172.8	-141.6	-106.1
EBITDA growth			11.6%	73.1%
Depreciation and amortization			0.5			0.5	0.3	0.1
EBIT [+]			-158.5	-184.1	-190.1	-173.3	-141.9	-106.3
EBIT growth			11.7%	73.2%
Non-recurring items					1.3
Interest expense			1.9			1.4	0.7	0.1
Interest expense			1.9	1.2	1.4	1.4	0.7	0.2
Other income (expense), net [+]			0.6	0.6	-0.1	0.1	0.1	0.1
Other non-ooperating expenses			0.0
Other			-0.2		-0.2
Pre-tax income			-161.1	-186.0	-192.8	-174.5	-142.5	-106.3
Income taxes			0.0	0.0	0.0	0.0	0.0	0.0
Tax rate			0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Net income			-161.1	-186.0	-192.8	-174.5	-142.5	-106.3

Basic EPS [+]			($4.11)	($4.83)	($5.10)	($4.65)	($4.38)	($4.09)
Growth			-6.2%	18.0%
Diluted EPS [+]			($4.11)	($4.83)	($5.10)	($4.65)	($4.38)	($4.09)
Growth			-6.2%	18.0%

Shares outstanding (basic) [+]			39.2	38.5	37.8	37.5	32.5	26.0
Growth			20.6%	48.2%
Shares outstanding (diluted) [+]			39.2	38.5	37.8	37.5	32.5	26.0
Growth			20.6%	48.2%

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.